The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Phase II study of alternate sunitinib schedule in patients with metastatic renal cell carinoma.
 
Eric Jonasch
Consulting or Advisory Role - Cerulean Pharma; Eisai; Exelixis; Genentech/Roche; Novartis; Pfizer
Research Funding - Exelixis; Novartis; Onyx; Pfizer
Travel, Accommodations, Expenses - Cerulean Pharma; Novartis; Pfizer
 
Rebecca Slack
No Relationships to Disclose
 
Daniel M. Geynisman
Consulting or Advisory Role - Exelixis; Novartis; Pfizer
Research Funding - Genentech (Inst); Merck (Inst); Millennium (Inst); Pfizer (Inst)
 
Matthew I. Milowsky
Research Funding - Acerta Pharma (Inst); BioClin Therapeutics (Inst); Bristol-Myers Squibb (Inst); Cerulean Pharma (Inst); Incyte (Inst); Innocrin Pharma (Inst); Inovio Pharmaceuticals (Inst); MedImmune (Inst); Merck (Inst); Mirati Therapeutics (Inst); Pfizer (Inst); Roche/Genentech (Inst); Seagen (Inst); X4 Pharma (Inst)
Travel, Accommodations, Expenses - Roche/Genentech
 
Kimryn Rathmell
Research Funding - Bristol-Myers Squibb (Inst); Calithera Biosciences (Inst); Incyte (I); Novartis (Inst); Peloton Therapeutics (Inst); Pfizer (Inst); TRACON Pharma (Inst)
 
Summer Stovall
No Relationships to Disclose
 
Donna Juarez
No Relationships to Disclose
 
Elizabeth R. Plimack
Consulting or Advisory Role - Acceleron Pharma; Acceleron Pharma; AstraZeneca/MedImmune; Bristol-Myers Squibb; Genentech/Roche; Lilly; Novartis; Synergene
Research Funding - Acceleron Pharma (Inst); AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Lilly (Inst); Merck Sharp & Dohme (Inst); Novartis (Inst); Peloton Therapeutics (Inst); Pfizer (Inst)
Patents, Royalties, Other Intellectual Property - U.S. Patent No.: 14/588,503, Filed 1/2/2015. (Inst)
 
Nizar M. Tannir
Honoraria - Argos Therapeutics; Bristol-Myers Squibb; Calithera Biosciences; Exelixis; Nektar; Novartis; Pfizer
Consulting or Advisory Role - Argos Therapeutics; Bristol-Myers Squibb; Calithera Biosciences; Exelixis; Nektar; Novartis; Pfizer
Research Funding - Bristol-Myers Squibb; Epizyme; Exelixis; Mirati Therapeutics; Novartis
Travel, Accommodations, Expenses - Argos Therapeutics; Argos Therapeutics; Bristol-Myers Squibb; Calithera Biosciences; Exelixis; Nektar; Novartis; Pfizer
 
Brian I. Rini
Consulting or Advisory Role - Pfizer
Research Funding - Bristol-Myers Squibb (Inst); Pfizer (Inst); Roche/Genentech (Inst)
Travel, Accommodations, Expenses - Pfizer